The PDE5 inhibitor dipyridamole is favourable in combination with low doses of acetylsalicylic acid (aspirin) as dual antiplatelet therapy for secondary prevention of ischemic stroke [17]. The gene discussed is PDE5A; the disease is ischemic stroke.